Unknown

Dataset Information

0

Secreted frizzled related protein 4 reduces fibrosis scar size and ameliorates cardiac function after ischemic injury.


ABSTRACT: Expression of the Wnt modulator secreted frizzled related protein 4 (Sfrp4) is upregulated after heart ischemic injury. We show that intramuscular administration of recombinant Sfrp4 to rat heart ischemic injury and recanalization models prevents further deterioration of cardiac function after the ischemic injury. The effect of Sfrp4 persisted for at least 20 weeks when Sfrp4 was administered in a slow release system (Sfrp4-polyhedra) to both acute and subacute ischemic models. The histology of the dissected heart showed that the cardiac wall was thicker and the area of acellular scarring was smaller in Sfrp4-treated hearts than in controls. Increased amounts of both the inactive serine 9-phosphorylated form of glycogen synthase kinase (GSK)-3? and the active form of ?-catenin were observed by immunohistology 3 days after lateral anterior descendant ligation in control, but not in Sfrp4-treated hearts. All together, we show that administration of Sfrp4 interferes with canonical Wnt signaling that could mediate the formation of acellular scar and consequently contributes to the prevention of aggravation of cardiac function.

SUBMITTER: Matsushima K 

PROVIDER: S-EPMC2965190 | biostudies-literature | 2010 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Secreted frizzled related protein 4 reduces fibrosis scar size and ameliorates cardiac function after ischemic injury.

Matsushima Kentaro K   Suyama Takashi T   Takenaka Chiemi C   Nishishita Naoki N   Ikeda Keiko K   Ikada Yoshito Y   Sawa Yoshiki Y   Jakt Lars Martin LM   Mori Hajime H   Kawamata Shin S  

Tissue engineering. Part A 20100723 11


Expression of the Wnt modulator secreted frizzled related protein 4 (Sfrp4) is upregulated after heart ischemic injury. We show that intramuscular administration of recombinant Sfrp4 to rat heart ischemic injury and recanalization models prevents further deterioration of cardiac function after the ischemic injury. The effect of Sfrp4 persisted for at least 20 weeks when Sfrp4 was administered in a slow release system (Sfrp4-polyhedra) to both acute and subacute ischemic models. The histology of  ...[more]

Similar Datasets

| S-EPMC3000293 | biostudies-literature
2020-06-04 | GSE151695 | GEO
2020-06-05 | GSE151834 | GEO
| S-EPMC7415659 | biostudies-literature
| S-EPMC8458704 | biostudies-literature
| S-EPMC4251970 | biostudies-literature
| S-EPMC5867110 | biostudies-literature
| S-EPMC8199077 | biostudies-literature
| S-EPMC6755450 | biostudies-literature
| S-EPMC5075919 | biostudies-literature